GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

The new dose strength for young infants is dissolvable, even in breast milk. Credit: Luma Pimentel/Unsplash. The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.